James Bearden to Lung Neoplasms
This is a "connection" page, showing publications James Bearden has written about Lung Neoplasms.
Connection Strength
0.493
-
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Oct; 1(8):832-6.
Score: 0.153
-
Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 03 01; 103(3):686-696.
Score: 0.089
-
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015 Jan; 10(1):172-80.
Score: 0.068
-
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007 Nov 01; 110(9):2027-34.
Score: 0.041
-
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007 Jun; 2(6):526-30.
Score: 0.040
-
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5.
Score: 0.039
-
A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Jul; 6(1):33-42.
Score: 0.033
-
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10.
Score: 0.030